Sichuan’s Ancocare Gets FDA Green Light for Phase I/III Study of Oncolytic Virus in Neuroblastoma

Sichuan-based Flavivirus technology platform developer Ancocare has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a Phase I/III clinical study for its double spear type I oncolytic virus DS1-H2-1 in neuroblastoma. The product, which leverages the Flavivirus technology platform, is a positive single-stranded RNA oncolytic virus derived from the modification of the West Nile virus. It employs dual mechanisms of tumor lysis and immune T cell activation, showing potential for the efficient treatment of various tumors, with particular promise in neurological tumors such as neuroblastoma and glioma. Early studies have indicated exceptionally high tumor inhibition rates.- Flcube.com